A clone of cells in which the regulation of purine metabolism is genetically altered was selected and isolated from chemically mutagenized HTC cells (a line of rat hepatoma cells in continuous culture). The clone, designated MAU V, was selected for increased ability to salvage exogenous purines by isolating it in medium containing methylmercaptopurine ribonucleoside, adenine, and uridine, in which medium wild-type cells cannot divide. We have characterized these cells as having an increased rate of de novo purine biosynthesis, apparently as the result of an altered phosphoribosylpyrophosphate (PRPP) synthetase. The altered enzyme has normal catalytic properties but an altered sensitivity to feedback inhibition by purine and pyrimidine nucleotides. The types of inhibitions (competitive and uncompetitive) exerted by AMP, ADP, and TDP on the wild-type enzyme have been maintained in the altered enzyme, but values for Ki have been increased by factors of 10, 17.5, and 5, respectively. The specific catalytic activities of AMP: pyrophosphate phosphoribosyltransferase and IMP:pyrophosphate phosphoribosyltransferase are normal. The mutant cell may serve as a model for a specific human disease, one type of dominantly inherited overproduction hyperuricemia.
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Purine biosynthesis in mammalian cells is regulated at numerous sites along the pathway (1) . The relative importance of each of these sites in maintenance of the physiologic state is unclear. Aberrant regulation can result in human disease, most notably overproduction hyperuricemia leading to gout (2) . We have been examining the regulation of purine biosynthesis in a line of rat hepatoma cells in continuous culture (HTC cells) (3), which we consider to be a model for the mammalian hepatocyte. Because of recent advances in the techniques for studying the genetics of somatic mammalian cells (4) (5) (6) , and because genetic approaches have been so profitably employed in studies of procaryotic regulatory mechanisms (7), we have attempted to isolate an HTC cell in which regulation of the purine pathway has been genetically altered.
From chemically mutagenized HTC cells we have selected a clone of cells for increased purine salvage capabilities. We Scintillation counting fluid consisted of 4 g of Omnifluor, 700 ml of toluene, and 250 ml of Triton X-100, except that the fluid used when counting Hyamine papers contained 300 ml of 95% ethanol instead of the Triton.
HTC cells were grown as suspension cultures or as monolayers in Swim's 77 medium (3) containing 2 mM L-glutamine and 10% (vol/vol) calf serum (growth medium). Cells in monolayer culture were mutagenized for 2 hr with 30 AM N-methyl-N-nitroso-N'-nitroguanidine, conditions under which approximately 50% of the population survive, and were allowed to recover for 3 days before being selected for their ability to grow in the simultaneous presence of methylmercaptopurine ribonucleoside (MMPR) (0.2 mM), adenine (0.2 mM), and uridine (0.5 mM). Cells of the two surviving colonies from eight T-flasks were dispersed into single-cell suspensions in separate spinner flasks; an aliquot was then cloned in "cloning medium" (Swim's 77 medium containing 10% calf serum and 10% fetal-calf serum, supplemented with 2 mM glutamine and 1 mM pyruvate) that contained 0.3 g of agar/ 100 ml and the selective agents MMPR, adenine, and uridine at the above concentrations. Clones were picked from the semi-solid medium, grown as monolayers in nonselective cloning medium, placed into suspension culture, and routinely maintained there under nonselective conditionss.
The rate of intracellular purine biosynthesis de novo was determined as previously described (8) . All enzyme assays were performed on cell-free extracts prepared at 40 in the following manner. Cells grown in suspension culture were harvested by centrifugation at 200 X g and washed once with phosphate-buffered saline (pH 7.0) (10). The cell pellet was then suspended in the appropriate buffer at a cell density of 3.3 X 107 cells per ml. For assaying adenosine 5'-monophosphate pyrophosphate phosphoribosyltransferase (APRTase) and inosine 5'-monophosphate pyrophosphate phosphoribosyltransferase (HGPRTase), the buffer used was 50 mM Tris HCl (pH 7.6), whereas, for PRPP synthetase we used 50 mM potassium phosphate (pH 7.4), 6 mM MgCl2, and 0.1 mM dithiothreitol. The cells were disrupted by sonication for 2-5 sec using a Bronwill Biosonik III set at 30% output.
The cell-free suspension was centrifuged at 20,000 X g for 20 min, and the supernatant was filtered through a column (10 X 1 cm) of fine Sephadex G-25 to remove all molecules of molecular weight less than 5000.
APRTase was assayed by measuring the production of ra- Regulatory Properties of PRPP Synthetase from MA U V Cells. PRPP synthetase has been reported to be sensitive to feedback inhibition both in bacteria (15, 16) and in mammalian cells (17) (18) (19) (20) . We compared the sensitivity to feedback inhibition of the enzyme from MAU V cells with the sensitivity of that from wild-type cells. We found that PRPP synthetase activity in gel-filtered, crude extracts from MAU V cells was significantly less inhibited by low concentrations of AMP, ADP, or TDP than was the enzyme in extracts of wild-type cells. The difference in response to ADP of the enzymes in the mutant and wild-type cells (Fig. 2) is similar to their different responses to the other two inhibitors we examined.
In view of the resistance to inhibition of PRPP synthetase from MAU V cells, we examined whether the type of inhibition remained the same as that for the enzyme in wild-type cells. Fig. 3 From the above data, values for the inhibitor constants (Ka) for the enzymes from the two cell lines were determined (21) ( Table 2 ). The sensitivity of the enzyme from MAU V cells to inhibition by AMP, ADP, and TDP is decreased 10-fold, 17.5-fold, and 5-fold, respectively.
Since these experiments were performed using crude extracts, it was possible that the difference between MAU V cells and wild-type cells lay not in an altered PRPP synthetase but in an increased ability on the part of extracts from MAU V cells to inactivate the inhibitor molecules or in the presence of some inhibitor antagonist that might act directly on the enzyme. If either were the case, one would expect that, upon mixing an equal quantity of enzyme activity (22) .
Some useful information which can be derived from our present studies concerns the mechanism by which AMP inhibits activity of the enzyme. Inhibition by AMP, an immediate product of the catalysis, is competitive with ATP, a substrate for the reaction; thus, one might suppose that AMP inhibits at the catalytic site. However, the Ki for AMP has been altered 10-fold in the mutant PRPP synthetase while the Km for ATP, as well as for R-5-P, has remained unchanged indicating that the mutation has not affected the catalytic site. Thus, it appears that AMP inhibits at a site other than the catalytic site, i.e., an allosteric site.
The overproduction of purines in cells containing a feedback-resistant PRPP synthetase demonstrates the importance of feedback inhibition of this enzyme in the normal regulation of the de novo purine pathway. In MAU V cells the enzyme continues to produce PRPP in the presence of concentrations of nucleotides at which it would normally be inhibited. The intracellular concentration of PRPP has been implicated as an important regulator of de novo purine synthesis (23) (24) (25) (26) , and our observations support this. PRPP apparently affects the purine pathway by influencing the equilibrium between active and inactive forms of PRPP glutamylamidotransferase (27) , the first enzyme unique to the purine pathway (1).
In lower organisms, mutations have been described that affect the feedback sensitivities of enzymes. These mutations range from complete loss of sensitivity (28, 29) to enhanced sensitivity (30, 31) to feedback inhibition, and have been Wild-type 10 
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Each Ki was determined from a plot of the reciprocal of the initial velocity versus the inhibitor concentration (21) .
associated with normal (30, 32, 33) or altered catalytic functions (32) . PRPP synthetase from MAU V cells is apparently the only reported feedback-resistant mammalian enzyme (33, 34) .
The overproduction of purines in man is associated with disease states (2, (35) (36) (37) . The biochemically delineated causes of overproduction hyperuricemia in man are all associated with altered PRPP metabolism (35, 36, 38, 39) . Two of these reported biochemical diseases directly involve the enzyme PRPP synthetase (34, 37) . In both instances the catalytic activities of the enzyme are increased in the absence of inhibitors. Although the maximal specific catalytic activity of PRPP synthetase from MAU V cells is not increased, it has abnormally high activity under physiologic conditions in the cell. Thus, if one were attempting to identify a mutant PRPP synthetase, examining the maximal specific catalytic activity of the enzyme in vitro would not detect the altered enzyme, nor would the defect be discovered by examining the activity of PRPP synthetase in the presence of maximally effective concentrations of inhibitors. To recognize the aberrancy, one would at least have to determine the Ki of the enzyme for the nucleotide inhibitor.
We suggest that our approach, that of constructing specific mutants of somatic mammalian cells in culture, can serve as a source of analogs of human biochemical diseases. These analogs might then provide experimental models for study of the molecular mechanisms underlying human pathologic conditions and provide suitable systems in which to explore new approaches to diagnosis and therapy.
NOTE ADDED IN PROOF
Sperling et al. (40) have recently described a PRPP synthetase with decreased sensitivity to feedback inhibition from the erythrocytes of one of two male siblings with overproduction hyperuricemia and gout.
